HELTON SANDRA L

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 8

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 962 shares

Expires 2028-06-07

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 7

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,925 shares

Expires 2028-02-22

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 6

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 962 shares

Expires 2029-06-06

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 5

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 962 shares

Expires 2030-06-10

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 4

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 962 shares

Expires 2031-06-09

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 3

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,133 shares

Expires 2032-06-08

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 2

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,566 shares

Expires 2033-06-08

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001104659-25-051347 · tm2515648-3_4seq1.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2034-06-06

F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').

F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).

SEC source: 0001494650-24-000089 · wk-form4_1717791972.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-06-06

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001494650-23-000065 · wk-form4_1686334276.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,500

Underlying: Common Stock · 53,500 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 8, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001062993-22-021024 · form4.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,747

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.03, inclusive. The reporting person undertakes to provide Principal Financial Group, Inc., any security holder of Principal Financial Group, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001062993-22-021005 · form4.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,245

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The reporting person undertakes to provide Principal Financial Group, Inc., any security holder of Principal Financial Group, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001062993-22-021022 · form4a.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,747

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The reporting person undertakes to provide Principal Financial Group, Inc., any security holder of Principal Financial Group, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · balance_after: Amendment filed to correct a prior inadvertent administrative error in Box 5 as shown on report filed 8/18/22 and subsequent filings, being corrected now.

SEC source: 0001752836-22-000155 · wf-form4_166567366799071.xml · derivative · entry 2

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,638 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

SEC source: 0001752836-22-000155 · wf-form4_166567366799071.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").

SEC source: 0001062993-22-018331 · form4.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,278

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.77 to $73.40, inclusive. The reporting person undertakes to provide Principal Financial Group, Inc., any security holder of Principal Financial Group, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001494650-22-000064 · wf-form4_165478449212222.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 8, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001752836-22-000069 · wf-form4_165247246304012.xml · derivative · entry 3

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,718 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001752836-22-000069 · wf-form4_165247246304012.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001752836-22-000069 · wf-form4_165247246304012.xml · derivative · entry 2

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,638

Underlying: Common Stock · 14,638 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001062993-22-008854 · form4.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,320

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-21-000230 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,762

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-21-000194 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,183

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-21-000162 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,567

F1 · price: Grant of restricted stock units.

SEC source: 0001494650-21-000068 · wf-form4_162335213464969.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,439

Underlying: Common Stock · 14,439 shares

Expires 2031-06-09

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 9, 2022 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2022 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001126328-21-000145 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,976

F1 · price: Grant of restricted stock units.

SEC source: 0001752836-21-000155 · wf-form4_162128243509672.xml · derivative · entry 2

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,089 shares

Expires 2021-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001752836-21-000155 · wf-form4_162128243509672.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,377

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001752836-21-000141 · wf-form4_162102323824868.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,718

Underlying: Common Stock · 7,718 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001126328-21-000121 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,464

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-20-000226 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,916

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-20-000185 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,225

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-20-000155 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,387

F1 · price: Grant of restricted stock units.

SEC source: 0001494650-20-000069 · wf-form4_159196282975137.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,439

Underlying: Common Stock · 14,439 shares

Expires 2030-06-09

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001126328-20-000132 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,572

F1 · price: Grant of restricted stock units.

SEC source: 0001752836-20-000113 · wf-form4_158957335472895.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,089

Underlying: Common Stock · 24,089 shares

Expires 2021-05-13

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001126328-20-000107 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,898

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-19-000263 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,526

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-19-000220 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,015

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-19-000182 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,532

F1 · price: Grant of restricted stock units.

F2 · balance_after: Corrects prior inadvertent administrative error.

SEC source: 0001494650-19-000056 · wf-form4_156017816132398.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,439

Underlying: Common Stock · 14,439 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2020 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2020 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001126328-19-000160 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,047

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-19-000116 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,065

F1 · price: Grant of restricted stock units.

SEC source: 0000899243-19-005743 · doc4.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,288

F1 · shares: Represents shares issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of Issuer's common stock. Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

SEC source: 0001126328-19-000005 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,565

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-18-000252 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,996

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-18-000195 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,585

F1 · price: Grant of restricted stock units.

SEC source: 0001494650-18-000059 · wf-form4_152875155270626.xml · derivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,439

Underlying: Common Stock · 14,439 shares

Expires 2028-06-06

F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 7, 2019 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2019 annual meeting of stockholders, subject to continued service with the Issuer.

SEC source: 0001126328-18-000164 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,143

F1 · price: Grant of restricted stock units.

SEC source: 0001126328-18-000123 · edgar.xml · nonDerivative · entry 1

HELTON SANDRA L · CIK 0001166857 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,391

F1 · price: Grant of restricted stock units.